logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY

Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of CASGEVY Conditional Approval for Both Sickle Cell Disease and Transfusion Dependent Beta Thalassemia Vertex Pharmaceuticals ( VRTX ) and CRISPR Therapeutics ( CRSP ) today announced that the United Kingdom (U.K.) Medicines...

Read More

November 16, 2023

0

Bausch + Lomb and Clearside Biomedical: FDA Approved XIPERE™ for Macular Edema Associated with Uveitis

Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ Bausch + Lomb, a leading global eye health business of  Bausch Health Companies ( BHC ),  and  Clearside Biomedical ( CLSD ) announced that the U.S. FDA approved XIPERE™...

Read More

October 25, 2021

0

Anavex Announced US Patent Office Granted a Patent No. 11,813.242 Entitled A273 a Therapeutic for Insomnia, Anxiety and Agitation

Anavex Life Sciences Granted US Patent Anavex Life Sciences ( AVXL ) – a development-stage biopharmaceutical company announced that the United States Patent and Trademark Office ( USPTO ) granted U.S. Patent No. 11,813,242 entitled “A273 as a therapeutic for insomnia, anxiety, and agitation.  This patent expands Anavex’s existing patent coverage of ANAVEX®273 (blarcamesine), including U.S. Patent No. 11,337,953 to cover Anavex’s leading drug candidate, ANAVEX®2-73, and NANVEX®14141...

Read More

November 22, 2023

0

Ionis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Ionis Pharmaceuticals  For three decades, Ionis Pharmaceuticals ( IONS ) invented medicines to treat serious diseases. Currently, Ionis has five marketed products and a wealthy pipeline in neurology, cardiology, and other areas of high patient need. Ionis is a pioneer...

Read More

February 21, 2024

0

Immunovant Inc: Positive IMVT-1402 Results that Would Confirm Best-in-Class Potential in Treating Autoimmune Diseases

Immunovant Inc in the NEWS Immunovant, Inc. ( IMVT ) announced initial data from 600 mg MAD cohort of a Phase 1 clinical trial of its product IMVT-1402 in healthy adults. The Phase 1 clinical trial is a randomized, double-blind,...

Read More

November 28, 2023

0

Carlisle Companies Inc and Arcturus Therapeutics Granted Approval in Japan of a Novel Self-Amplifying mRNA Vaccine for COVID-19  

Carlisle Companies Inc and Arcturus Therapeutics in the NEWS Today, November 28, 2023, Global biotechnology leaders Carlisle Companies Inc ( CSL )  and Arcturus Therapeutics ( ARCT ) announced that Japan's Ministry of Health, Labor and Welfare ( MHLW ) granted...

Read More

November 28, 2023

0

Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

Vertex Pharmaceuticals in the NEWS Vertex Pharmaceuticals ( VRTX ) announced that the European Medicines Agency’s ( EMA’s ) Committee for Medicinal Products for Human Use ( CHMP ) adopted a positive opinion for the label expansion of KALYDECO ®...

Read More

February 23, 2024

0

AbbVie Inc to Acquire ImmunoGen

AbbVie Inc Acquisition of Immunogen in the News AbbVie Inc. ( ABBV ) and ImmunoGen ( IMGN ) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug...

Read More

November 30, 2023

0

Krystal Biotech Announced Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Krystal Biotech Today, February 26, 2024, Krystal Biotech ( KRYS ) firm announces its full year financial results and business updates.  Read this press release to learn about the company. New England Journal of Medicine publication of the use of...

Read More

February 26, 2024

0

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

Verrica Pharmaceuticals   Verrica Pharmaceuticals ( VRCA ) is a dermatology therapeutics company developing medications for skin diseases.  Today Verrica announced financial results for the fourth quarter and year ended December 31, 2023. Ted White, Verrica Pharmaceuticals' President and Chief...

Read More

February 29, 2024

0

  • Previous
  • 1
  • 2
  • ...
  • 150
  • 151
  • 152
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy